2021
DOI: 10.1186/s12917-021-02943-5
|View full text |Cite
|
Sign up to set email alerts
|

Research article expression of surfactant protein-A and D, and CD9 in lungs of 1 and 30 day old foals

Abstract: Background Respiratory diseases are a major cause of morbidity and mortality in the horses of all ages including foals. There is limited understanding of the expression of immune molecules such as tetraspanins and surfactant proteins (SP) and the regulation of the immune responses in the lungs of the foals. Therefore, the expression of CD9, SP-A and SP-D in foal lungs was examined. Results Lungs from one day old (n = 6) and 30 days old (n = 5) foal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…It could be reasonably hypothesized that surfactant therapy would be promising in COVID-19 cases. A list of approved lung surfactants Colfosceril palpitate, breakfast, lucinactant, and recombinant human surfactants protein C. polysorbate, poloxamer, sodium lauryl sulfate, Certificate, Bile Salt Surfactants, Phospholipids, Vitamin E TPGS, Polyoxyl 35 castor oil [29][30][31][32][33][34][35][36].…”
Section: Surfactant Therapy For Respiratory Illnessmentioning
confidence: 99%
“…It could be reasonably hypothesized that surfactant therapy would be promising in COVID-19 cases. A list of approved lung surfactants Colfosceril palpitate, breakfast, lucinactant, and recombinant human surfactants protein C. polysorbate, poloxamer, sodium lauryl sulfate, Certificate, Bile Salt Surfactants, Phospholipids, Vitamin E TPGS, Polyoxyl 35 castor oil [29][30][31][32][33][34][35][36].…”
Section: Surfactant Therapy For Respiratory Illnessmentioning
confidence: 99%